Roche has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US.

Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research. With its large network of community oncology practices and academic medical centers across the US, Flatiron Health has created a technology platform designed to learn from the experience of every patient.

Under the terms of the agreement, the transaction value for the acquisition of Flatiron Health was USD 1.9 billion on a fully diluted basis, subject to certain adjustments. Flatiron Health will continue its operations as a separate legal entity and its current business model, network of partnerships and overall objectives remain. The integrity of segregated patient protected health information will be preserved, as will dedicated sales and marketing, provider-facing and life science business activities.

As oncology leaders in their respective fields, the acquisition allows both companies to accelerate progress towards data-driven personalised healthcare in cancer.

Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. The Flatiron platform enables cancer researchers and care providers to learn from the experience of every patient.